Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Immunochemotherapy

Immunochemotherapy

12

Pipeline Programs↗

13

Active Trials↗

6

Companies Involved↗

Immunochemotherapy is an emerging landscape with 12 programs across 6 companies. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

75/100

Attrition Rate

5/100

Pipeline

Programs by Phase

Preclinical1

CTLA-4 Antibody

Western Regional Medical Center

Phase 1

No programs

Phase 27

Adebrelimab Combined With DOS

Tang-Du Hospital

ZR2 RDHAP

Zhejiang Cancer Hospital

Platinum Doublet

Regeneron

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Camrelizumab

Sun Yat-sen University

Phase 34

Pd-1inhibitor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

R-IDARAM Plus Intrathecal Chemotherapy

Navy General Hospital, Beijing

Pembrolizumab

Merck & Co.

Immunotherapy

Bristol-Myers Squibb

Approved

No programs

Analysis

Modality Breakdown

83%

Small molecule

10 of 12 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.

Analysis

Trial Status

21

clinical trials

Recruiting10 · 48%

Unknown status4 · 19%

Not yet recruiting3 · 14%

Completed3 · 14%

Withdrawn1 · 5%

Clinical Trials

Trial Activity

21 trials

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

Recruiting·UUniversity Hospital, Bonn·Phase 2·NCT06810609·176 enrolled

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Recruiting·TTongji Hospital·Phase 2·NCT06288360·40 enrolled

Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

Recruiting·NNavy General Hospital, Beijing·Phase 2/3·NCT02836158·100 enrolled

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

Recruiting·HHunan Province Tumor Hospital·Phase 3·NCT05549037·210 enrolled

Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting·FFondazione Italiana Linfomi - ETS·Phase 3·NCT04442412·430 enrolled

Neoadjuvant Immunochemotherapy for LAOSCC

Recruiting·—·Phase 3·NCT06258811·134 enrolled

Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

Recruiting·NNavy General Hospital, Beijing·Phase 2/3·NCT02657785·100 enrolled

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05980715·324 enrolled

ZR2 Sequential Immunochemotherapy for Newly Treated MCL

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT05992597·48 enrolled

PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC

Recruiting·SSun Yat-sen University·Phase 2·NCT06977074·83 enrolled

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT07452601·90 enrolled

PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07090707·50 enrolled

Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial

Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 1/2·NCT07190027·246 enrolled

Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC

Completed·GGuangdong Provincial People's Hospital·N/A·NCT05637580·110 enrolled

Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC

Completed·—·N/A·NCT07236320·200 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)